Potential evolution of neurosurgical treatment paradigms for craniopharyngioma based on genomic and transcriptomic characteristics

Leslie C. Robinson, MD, PharmD, MBA, Sandro Santagata, MD, PhD, and Todd C. Hankinson, MD, MBA

Pediatric Neurosurgery, Children’s Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado; and Department of Pathology, Brigham and Women’s Hospital, Boston Children’s Hospital, Harvard Institute of Medicine, Boston, Massachusetts

The recent genomic and transcriptomic characterization of human craniopharyngiomas has provided important insights into the pathogenesis of these tumors and supports that these tumor types are distinct entities. Critically, the insights provided by these data offer the potential for the introduction of novel therapies and surgical treatment paradigms for these tumors, which are associated with high morbidity rates and morbidity conditions. Mutations in the CTNNB1 gene are primary drivers of adamantinomatous craniopharyngioma (ACP) and lead to the accumulation of β-catenin protein in a subset of the nuclei within the neoplastic epithelium of these tumors. Dysregulation of epidermal growth factor receptor (EGFR) and of sonic hedgehog (SHH) signaling in ACP suggest that paracrine oncogenic mechanisms may underlie ACP growth and implicate these signaling pathways as potential targets for therapeutic intervention using directed therapies. Recent work shows that ACP cells have primary cilia, further supporting the potential importance of SHH signaling in the pathogenesis of these tumors. While further preclinical data are needed, directed therapies could defer, or replace, the need for radiation therapy and/or allow for less aggressive surgical interventions. Furthermore, the prospect for reliable control of cystic disease without the need for surgery now exists. Studies of papillary craniopharyngioma (PCP) are more clinically advanced than those for ACP. The vast majority of PCPs harbor the BRAFV600E mutation. There are now 2 reports of patients with PCP that had dramatic therapeutic responses to targeted agents. Ongoing clinical and research studies promise to not only advance our understanding of these challenging tumors but to offer new approaches for patient management.

https://thejns.org/doi/abs/10.3171/2016.9.FOCUS16308

KEY WORDS craniopharyngioma genomics; craniopharyngioma transcriptomics; CTNNB1; BRAF; papillary craniopharyngioma; adamantinomatous craniopharyngioma

The pathobiology of human craniopharyngioma is incompletely understood. This limitation has significantly hindered the ability of clinicians to manage patients afflicted by these tumors, which are associated with high morbidity rates and morbidity conditions. The last decade, however, has seen a number of critical discoveries that promise to transform therapeutic approaches. Analyses of the craniopharyngioma genome and transcriptome as well as of the DNA methylation patterns of craniopharyngioma have provided considerable insights into the origins of these tumors and into the drivers of their growth. This work supports that adamantinomatous (ACP) and papillary (PCP) craniopharyngioma are genetically distinct entities and has led to the description of tailored therapies for PCP. In this review we discuss the current knowledge regarding the genomic and transcriptomic characteristics of both ACP and PCP and the potential relevance for neurosurgical practice.

Adamantinomatous Craniopharyngioma

β-Catenin and the WNT/Wingless Pathway

The WNT/wingless pathway contains the only known recurrent genome aberration in ACP. In the normal physiological state, Wnt/wingless signaling is involved in organogenesis and adult stem cell maintenance. Among the
key members of the canonical WNT signaling pathway is β-catenin, which is encoded by the CTNNB1 gene.\textsuperscript{10,32} This protein plays a critical role in development, cellular proliferation, differentiation, and cell migration.\textsuperscript{10,11,16,41} A destruction complex restrains β-catenin within the cytosol and facilitates its ubiquitination and proteasomal degradation.\textsuperscript{31} The Wnt protein family includes approximately 20 different proteins that bind to the Frizzled (Fz) family of receptors. When Wnt proteins bind the Fz receptors, the Wnt pathway is activated,\textsuperscript{31} leading to an intracellular signaling cascade that ultimately prevents formation of the β-catenin destruction complex.\textsuperscript{9,11,16,22,31} Without the destruction complex, β-catenin protein accumulates and ultimately translocates to the nucleus, where it facilitates transcription of β-catenin target genes and stimulates cellular proliferation and other Wnt regulated cellular processes.\textsuperscript{8,9,11,16,22,31}

Increased migratory capacity and invasiveness have been observed in neoplastic cells with elevated β-catenin levels and activated target genes.\textsuperscript{22} In ACP, β-catenin accumulation can be found within cell clusters localized at invasive protrusions of tumor into normal brain\textsuperscript{22} (Fig. 1A). It is possible that this increased mobility and invasive capacity are related to the overexpression of fascin-1 (fascin), a β-catenin/T-cell factor (TCF) signaling target gene that is commonly involved with reorganization of the actin cytoskeleton, which is required for cellular motility.\textsuperscript{22,23} β-catenin can regulate fascin expression by binding to a TCF-binding domain on the promoter region for fascin.\textsuperscript{24} Other cancers, such as colorectal, have increased fascin expression, particularly at the invasive edges.\textsuperscript{25} β-catenin binding of fascin promotes reallocation of β-catenin, changes cell adhesion properties, and reduces β-catenin destruction.\textsuperscript{22} As β-catenin accumulates it can reduce E-cadherin expression, which reduces cell adhesion and likely leads to cells that are more motile and, consequently, more invasive.\textsuperscript{22} Inhibition of fascin or β-catenin expression can decrease the migratory capacity of ACP tumor cells in culture.\textsuperscript{22}

**ACP Genome Analyses**

**CTNNB1 Mutation**

Nuclear accumulation of β-catenin results from mutations within exon 3 of the CTNNB1 gene. This exon encodes a degradation targeting motif, mutation of which confers resistance to the β-catenin destruction complex.\textsuperscript{9,41} While mutations have been identified at a number of different codons, these all impact the binding of GSK3β.\textsuperscript{9,11,12,24,28,38} As a result of this mechanism, nuclear accumulation of β-catenin is a histological hallmark of CTNNB1 mutation.\textsuperscript{10,12,16,26,41} In the case of craniopharyngiomas, mutation of CTNNB1 has been described in 69%–100%\textsuperscript{9,20,28} of ACP specimens, while it is not routinely observed in PCP or other parasellar tumors.\textsuperscript{9,28} In the most detailed study to date, CTNNB1 mutation was identified in 95% of ACP specimens, using massively parallel sequencing and targeted genotyping.\textsuperscript{5} In the same study, Brastianos and Santagata determined that CTNNB1 mutation was not present in PCP.\textsuperscript{5} Other groups have identified CTNNB1 mutation in 70%–80% of ACP specimens.\textsuperscript{9,12,19,31} Sampling error or
the significant intratumoral heterogeneity present in these tumors, which often have scant neoplastic epithelium, may explain the variability in the frequency with which CTNNB1 mutation is detected. Presently, however, despite the presence of β-catenin dysregulation in multiple cancer cell types, no targeted therapies are available. As such, direct intervention regarding CTNNB1 mutation is unlikely to impact neurosurgical treatment algorithms in the short term.

Nevertheless, insights related to the mutation affecting the GSK3β binding domain of CTNNB1 have implications regarding the origins of ACP. A clearer understanding of these may facilitate efforts to identify directed therapies. For example, definitive evidence of pituitary origin would indicate that ACP is not protected by the blood-brain barrier, thereby suggesting that a wider range of systemically delivered antitumor therapies could be effective. While similar mutations are observed in other lesions that share histological features with ACP, such as pilomatrixoma and calcifying cystic odontogenic tumor, multiple potential origins for ACP remain to be explored. As mentioned above, it has been postulated that ACP arises from undifferentiated anterior pituitary stem cells. An additional potential mechanism employs the paracrine tumorigenesis theory, in which small clusters of CTNNB1 mutated cells, characterized by nucleocytoplasmic β-catenin, leverage paracrine/autocrine signaling to promote tumorigenic activity in a much larger nonmutated cell population.

The Sonic Hedgehog Pathway

Sonic hedgehog (SHH) plays an integral role in the maintenance of adult stem cells and in the normal development of several organs, including the pituitary gland and Rathke’s pouch. Pathological upregulation of SHH signaling has been demonstrated in a multitude of cancers, including meningioma, basal cell carcinoma, and medulloblastoma. With regard to ACP, SHH overexpression has been described in tumors in humans and in a novel murine model, in which it colocalizes in cells with nuclear β-catenin (Fig. 1B). It is hypothesized that both autocrine and paracrine SHH signaling may contribute to ACP tumorigenesis. Two studies of the human ACP transcriptome have shown an upregulation of SHH pathway genes in ACP—of SHH protein, and cell culture models. Additional evidence supporting the role of EGFR in tumorigenesis of ACP includes high levels of EGF pathway genes in the ACP transcriptome, the involvement of EGFR in the regulation of the expression of stem cell markers in ACP, and the presence of the activated EGFR pathway in β-catenin accumulating cells. As with therapies directed at the SHH pathway, those targeting the EGFR pathway require further clarification through preclinical study before they could enter clinical use and impact neurosurgical care.

Additional Relevant Pathways

In addition to SHH and EGFR pathways, other molecules and pathways are uniquely expressed in craniopharyngioma, but are not yet as well described. The ACP transcriptome is characterized by high levels of certain matrix metallopeptidases, including MMPs 2, 3, 7, 9, and 12. Elevated levels of p63 have been found in both ACP and PCP, with elevated expression also identified in the ACP transcriptome. P63 is a gene homolog of the p53 tumor suppressor family. Impaired p63 expression has been suggested to influence neoplastic cell transformation. In addition, transcriptome analysis identified significant overexpression—in ACP—of LCK, EPHA, and SRC, each of which is a target of the tyrosine kinase inhibi-
itor dasatinib. While still in the preclinical stages, these unique characteristics of ACP may at some point allow for effective therapeutic intervention without radical surgery.

Neurosurgical Implications of ACP

While current therapy for ACP relies upon surgery, radiation, or cyst-directed intervention, the biological characteristics described above hold promise for the introduction of targeted antitumor treatments. The details of therapy delivery, such as the timing and route (e.g., systemic, intrathecal), and therefore the precise role of operative intervention, remain to be determined. Presently, preclinical studies to identify the paradigms with the highest likelihood of success are ongoing.

Papillary Craniopharyngioma

Distinction From ACP

As described above, ACP and PCP demonstrate distinct genetic aberrations. Different transcriptome profiles

**Fig. 2.** A–C: Expression of the indicated developmental and cancer-related genes in individual ACP samples: EGF genes (A), WNT pathway (B), and SHH pathway (C). D: Western blot analysis demonstrating overexpression of the latent preforms and active cleaved protein isoforms of SHH in ACP relative to other common pediatric brain tumors and normal brain. ATRT = atypical teratoid/rhabdoid tumor; EPN = ependymoma; GBM = glioblastoma; MED = medulloblastoma; Norm = normal brain; PA = pilocytic astrocytoma. Reproduced with slight modification from Gump et al: Acta Neuropathol Commun 3:30, 2015; CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/).
BRAF mutations that harbor medications that were developed in the context of other tumors, raised the potential for effective targeted therapy using BRAF inhibitors. This mutation in 92.8% of PCP specimens. This mutation was demonstrated in the context of multiple human cancers, making it the most clinically relevant genome-level aberration that has been identified in human craniopharyngioma. BRAF mutation upregulates MAP kinase signaling, thereby driving cell division. Although multiple mutations of BRAF have been described in human cancers, the most common is a substitution of valine by glutamate at codon number 600, termed the BRAF V600E mutation. The work of Brastia and colleagues described a near-total radiographic response of a BRAF V600E mutant PCP following treatment with single agent vemurafenib, a mutation-specific BRAF inhibitor. Importantly, after therapy was halted for a CSF leak associated with tumor shrinkage, tumor recurrence occurred within 6 weeks and long-term control was not achieved after therapy was restarted. In a 39-year-old patient with multiply recurrent PCP, who had required 4 craniotomies and an endonasal resection for multiple cystic recurrences, Brastianos and colleagues reported an excellent initial response to combination therapy using the RAF inhibitor dabrafenib and MEK inhibitor trametinib (Fig. 3). Furthermore, the authors identified BRAF V600E mutant DNA in the patient’s peripheral blood during therapy, thus presenting the prospect of noninvasive diagnosis for patients with suspected PCP. These reports highlight the facts that multiple directed therapies are potentially available for patients with PCP and that dual or multiagent therapy is likely to be required to reliably obtain durable tumor control. As such, a multi-institutional trial of combined BRAF and MEK inhibition for patients with PCP is forthcoming.

In addition to offering therapeutic potential, the high prevalence of the BRAF V600E mutation in PCP may simplify diagnosis of these tumors. A mutation-specific antibody (clone VE1) recognizes the BRAF V600E mutant protein but not the wild-type protein. This is now being employed by pathologists for immunohistochemical identification, thereby distinguishing PCP from other masses...
of the sellar region, including pituitary adenomas, ACP, and Rathke’s cleft cysts with squamous metaplasia.\textsuperscript{27,30,37} Targeted genotyping of the BRAF\textsuperscript{V600E} mutant allele is also used for diagnosis and other biomarkers have been proposed as well.\textsuperscript{14}

**Neurosurgical Implications of PCP**

For neurosurgeons, the potential impact of recent advances in our biological understanding of PCP, as well as noninvasive identification of BRAF mutated cells, is considerable. Neoadjuvant systemic therapy that does not necessitate aggressive (or any) surgical intervention could assume a prominent position in the treatment paradigm for patients with PCP. While PCP represents the minority of craniopharyngiomas, and is almost exclusively limited to the adult population, this represents dramatic progress in the clinical management of this tumor associated with high morbidity.

**Conclusions**

Prospects for effective novel therapies against craniopharyngiomas in humans have improved considerably with recent advances in our understanding of the biological basis of this disease. Genomic and transcriptomic analyses indicate that ACP and PCP will require different logical basis of this disease. Genomic and transcriptomic analyses indicate that ACP and PCP will require different therapeutic approaches. Promising options for PCP have emerged from previous experience with more common tumors that harbor the BRAF\textsuperscript{V600E} mutation, and human clinical trials will further investigate these advances. These trials may allow neurosurgeons to reserve aggressive intervention, with the associated morbidity, for the minority of cases that do not demonstrate a durable response to directed therapies. Although we currently lack therapies that target the β-catenin mutation that characterizes ACP, multiple additional targets, such as the SHH and EGFR pathways, have been described. Further preclinical investigation of these prospects is ongoing and may ultimately, as in the case of PCP, influence neurosurgical management paradigms.

**References**

13. Hölsken A, Gebhardt M, Buchfelder M, Fahldibusch R,
35. Martinez-Barbera JP, Andoniadou CL: Concise review: Para-

Disclosures
The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Author Contributions
Conception and design: all authors. Acquisition of data: all authors. Analysis and interpretation of data: all authors. Drafting the article: all authors. Critically revising the article: all authors. Reviewed submitted version of manuscript: all authors. Approved the final version of the manuscript on behalf of all authors: Hankinson.

Correspondence
Todd C. Hankinson, Department of Pediatric Neurosurgery, Children’s Hospital Colorado, 13123 E 16th Ave., Box 330, Aurora, CO 80045. email: todd.hankinson@childrenscolorado.org.